Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Tisotumab vedotin by Genmab for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
Tisotumab vedotin is under clinical development by Genmab and currently in Phase II for Recurrent Head And Neck Squamous Cell...
Epcoritamab by Genmab for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Epcoritamab is under clinical development by Genmab and currently in Phase II for Relapsed Chronic Lymphocytic Leukemia (CLL). According to...
Tisotumab vedotin by Genmab for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Tisotumab vedotin is under clinical development by Genmab and currently in Phase II for Head And Neck Squamous Cell Carcinoma...
Tisotumab vedotin by Genmab for Epithelial Ovarian Cancer: Likelihood of Approval
Tisotumab vedotin is under clinical development by Genmab and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData,...
Tisotumab vedotin by Genmab for Peritoneal Cancer: Likelihood of Approval
Tisotumab vedotin is under clinical development by Genmab and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase...
Tisotumab vedotin by Genmab for Metastatic Colorectal Cancer: Likelihood of Approval
Tisotumab vedotin is under clinical development by Genmab and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData,...
Tisotumab vedotin by Genmab for Esophageal Cancer: Likelihood of Approval
Tisotumab vedotin is under clinical development by Genmab and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase...
Tisotumab vedotin by Genmab for Fallopian Tube Cancer: Likelihood of Approval
Tisotumab vedotin is under clinical development by Genmab and currently in Phase II for Fallopian Tube Cancer. According to GlobalData,...
Tisotumab vedotin by Genmab for Endometrial Cancer: Likelihood of Approval
Tisotumab vedotin is under clinical development by Genmab and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...
Tisotumab vedotin by Genmab for Solid Tumor: Likelihood of Approval
Tisotumab vedotin is under clinical development by Genmab and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
Tisotumab vedotin by Genmab for Bladder Cancer: Likelihood of Approval
Tisotumab vedotin is under clinical development by Genmab and currently in Phase II for Bladder Cancer. According to GlobalData, Phase...
Tisotumab vedotin by Genmab for Pancreatic Cancer: Likelihood of Approval
Tisotumab vedotin is under clinical development by Genmab and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...
Tisotumab vedotin by Genmab for Ovarian Cancer: Likelihood of Approval
Tisotumab vedotin is under clinical development by Genmab and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...
Epcoritamab by Genmab for Mantle Cell Lymphoma: Likelihood of Approval
Epcoritamab is under clinical development by Genmab and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData, Phase...
Epcoritamab by Genmab for Marginal Zone B-cell Lymphoma: Likelihood of Approval
Epcoritamab is under clinical development by Genmab and currently in Phase II for Marginal Zone B-cell Lymphoma. According to GlobalData,...
GEN-3014 by Genmab for Refractory Acute Myeloid Leukemia: Likelihood of Approval
GEN-3014 is under clinical development by Genmab and currently in Phase II for Refractory Acute Myeloid Leukemia. According to GlobalData,...
GEN-3014 by Genmab for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
GEN-3014 is under clinical development by Genmab and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to GlobalData,...
GEN-3014 by Genmab for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
GEN-3014 is under clinical development by Genmab and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to GlobalData,...
GEN-3017 by Genmab for T-Cell Lymphomas: Likelihood of Approval
GEN-3017 is under clinical development by Genmab and currently in Phase II for T-Cell Lymphomas. According to GlobalData, Phase II...
PRO-1184 by Genmab for Endometrial Cancer: Likelihood of Approval
PRO-1184 is under clinical development by Genmab and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II...